Thus, while treatment of cell lines revealed a distinct association with SF3B1 mutations, primary CLL cells displayed sensitivity to I-BRD9 treatment independent of SF3B1 mutation status. The gene discussed is SF3B1; the disease is B-cell chronic lymphocytic leukemia.